Kantakari is a classical Ayurvedic respiratory herb known botanically in current plant taxonomy as Solanum virginianum L.; the Ayurvedic Pharmacopoeia of India records the official drug as the mature dried whole plant of Solanum surattense Burm. f., synonym Solanum xanthocarpum Schrad. & Wendl. It is a very prickly herb of waste places, found widely across India, and is also known in Hindi by names such as Katai, Katali, Ringani, Bhatakataiya, and Chhotikateri.

Its importance in Ayurveda comes from its action on the respiratory channels and from its place in classical compound formulations. The Ayurvedic Pharmacopoeia describes its therapeutic uses under shvasa (breathlessness/asthmatic breathing), kasa (cough), pinasa (rhinitis), svarabheda (hoarseness of voice), jvara (fever), aruci (loss of taste/appetite), and parshvashula (pain in the flank or chest region). This makes Kantakari one of the important herbs used when Kapha-type congestion, cough, throat irritation, and obstructed breathing are present.

In Ayurvedic pharmacology, Kantakari is described as katu (pungent) and tikta (bitter) in taste, laghu (light) and ruksha (dry) in quality, ushna virya (hot in potency), and katu vipaka (pungent after digestion). These qualities explain its traditional use in Kapha-dominant respiratory patterns: the light, drying, warming profile is suited to liquefying and clearing thick Kapha while supporting dipana and pachana, the digestive actions that Ayurveda links with reduction of ama and channel obstruction.

Phytochemical Profile: Glucoalkaloids, Sterols and Respiratory-Relevant Constituents

The Ayurvedic Pharmacopoeia lists glucoalkaloids and sterols as constituents of Kantakari. Later phytochemical work has described steroidal alkaloids and glycoalkaloids such as solasodine, solasonine, solamargine, solanocarpine, and related compounds, along with sterols, saponins, flavonoids, and other plant constituents. These compounds help explain why Kantakari has drawn attention in respiratory, anti-inflammatory, antitussive, and antiallergic pharmacology, while the classical Ayurvedic explanation remains rooted in its rasa, guna, virya, vipaka, and karma.

Human Respiratory Studies and Traditional Clinical Use

Human studies on Kantakari and Kantakari-containing preparations are generally small, but they align with the herb’s traditional use in cough and asthma-like breathing difficulty. A pilot study in the Journal of Ethnopharmacology evaluated a single 300 mg oral dose of whole-plant Solanum xanthocarpum powder in people with mild to moderate bronchial asthma and recorded improvement in spirometric parameters within two hours, though the effect was lower than standard bronchodilator medicines used for comparison.

A later clinical paper in Phytotherapy Research investigated Solanum xanthocarpum and Solanum trilobatum at 300 mg three times daily for three days in mild to moderate bronchial asthma. The study belongs to the small clinical literature that supports the traditional respiratory role of Kantakari while keeping it as an adjunctive herb rather than a replacement for emergency asthma treatment.

Kantakari Avaleha, a linctus preparation built around Kantakari, has also been evaluated in bronchial asthma. In an open-label randomized controlled clinical trial published in AYU, 69 patients with mild to moderate bronchial asthma were randomized to Kantakari Avaleha or Kantakari Avaleha granules. Both forms were given as 6 g with lukewarm water before breakfast and dinner for 60 days, with a 30-day follow-up; both groups improved on asthma-related assessment parameters, and the granule form was considered a practical substitute for the avaleha form.

Classical Formulations and Practical Use

The Ayurvedic Pharmacopoeia lists Kantakari Avaleha, Panchatiktaka Ghrita, and Vyaghriharitaki among important formulations containing Kantakari. Kantakari Avaleha is described in later pharmaceutic reviews as an avaleha or linctus used especially in shvasa and kasa, with classical references also extending it to hikka and other conditions. Because avaleha preparations are sweet, semi-solid and soothing to the throat, they fit the traditional use of Kantakari in cough, throat irritation, hoarseness and Kapha-dominant respiratory complaints.

Vyaghriharitaki Avaleha is another important Kantakari-based formulation. In this formulation, Kantakari is combined with Haritaki, jaggery, Trikatu spices, aromatic herbs, and honey. A clinical study in chronic bronchitis used 10 g twice daily with lukewarm water before meals for 12 weeks and recorded improvement in cough and respiratory quality-of-life measures. This supports the classical logic of using Kantakari not only as a single herb but as part of well-designed compound preparations.

Kanakasava is a separate fermented respiratory formulation in which Kantakari appears along with herbs such as Vasa, Pippali, Yashtimadhu, Bharangi, Shunthi, Talisapatra, and other ingredients. It is traditionally placed in the context of hikka and shvasa, but because it contains stronger ingredients such as purified Datura in many classical versions, it should be used only under professional supervision.

Dosage Forms: Decoction, Avaleha and Compound Preparations

For the crude whole plant, the Ayurvedic Pharmacopoeia gives a decoction dose of 20–30 g of the drug for adults as general guidance. In practice, the final dose, form, duration and anupana are selected by a qualified Ayurvedic practitioner based on the patient’s strength, age, digestive capacity, season, type of cough, degree of Kapha accumulation, and whether the case is acute, recurrent or chronic.

Kantakari Avaleha and Vyaghriharitaki Avaleha illustrate the more common classical approach: Kantakari is often given in a compound preparation rather than alone. Avaleha preparations are especially suitable where cough, throat dryness, hoarseness, irritation and recurrent expectoration are present, while decoction forms are preferred when a lighter, Kapha-clearing preparation is desired.

Honey is a frequent anupana in respiratory formulations, but it should not be heated or boiled. Lukewarm water, milk or other vehicles may be chosen depending on the formulation and the person’s constitution. People with diabetes, pregnancy, significant gastric irritation, severe debility, or those taking multiple medications should not self-prescribe sweet avaleha preparations or concentrated respiratory herbs.

Kantakari in Dashamoola: Context Matters

Kantakari is one of the herbs of Laghu Panchamoola, the “five small roots” group that commonly includes Shalaparni, Prishniparni, Brihati, Kantakari and Gokshura. Together with the five large roots of Brihat Panchamoola, these form Dashamoola, the ten-root group widely used in Ayurveda for Vata and Kapha disorders, inflammatory states, pain, respiratory imbalance and postpartum or convalescent formulations.

This Dashamoola context is important because classical Ayurveda rarely treats respiratory conditions with only one isolated herb. Kantakari brings a warming, drying, throat-supporting and Kapha-clearing action; Brihati supports a closely related respiratory role; Shalaparni and Prishniparni add strengthening and balancing effects; Gokshura supports the lower channels and Vata regulation. In a complete Dashamoola preparation, these actions are arranged as a broader formula rather than a single-ingredient intervention.

For readers studying broader Ayurvedic respiratory care, Kantakari’s role can be understood alongside cleansing, oleation, fomentation, diet correction, rasayana and nasal therapies. The classical panchakarma framework is discussed in the panchakarma complete guide, while the respiratory and nasal route of care is introduced in nasya therapy Ayurvedic nasal treatment.

Safety and Responsible Use

Kantakari is a valuable Ayurvedic respiratory herb, but asthma and chronic breathlessness require proper medical diagnosis and monitoring. Kantakari, Kantakari Avaleha, Dashamoola, Kanakasava or any other herbal preparation should not replace prescribed bronchodilators, inhaled corticosteroids, antibiotics, emergency care or an asthma action plan. Anyone with wheezing, chest tightness, recurrent night cough, low oxygen, fever, chronic bronchitis, COPD, pregnancy, diabetes, kidney or liver disease, or regular medication use should consult a qualified Ayurvedic practitioner and a healthcare provider before using Kantakari therapeutically.

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.

References

1. Powo (powo.science.kew.org)
2. Ayurvedic Pharmacopoeia of India
3. Researchgate (researchgate.net)
4. Tsijournals (tsijournals.com)
5. Ajpsonline (ajpsonline.com)
6. Journals (journals.elsevier.com)
7. Cabidigitallibrary (cabidigitallibrary.org)
8. Onlinelibrary (onlinelibrary.wiley.com)
9. Res (res.cmb.ac.lk)
10. Researchgate (researchgate.net)
11. NCBI
12. Doaj (doaj.org)
13. Ctri (ctri.nic.in)
14. Researchgate (researchgate.net)
15. Jaims (jaims.in)
16. A critical review on two types of Laghupanchamula (2012), PubMed Central
17. Researchgate (researchgate.net)
18. Sciencedirect (sciencedirect.com)
19. Nhlbi (nhlbi.nih.gov)
20. CDC
21. Ayush (ayush.delhi.gov.in)

Kutaja is one of Ayurveda’s clearest digestive herbs for atisara and pravahika—loose stool, dysentery-like presentations, and bowel conditions marked by excessive intestinal fluid, mucus, griping, and impaired digestive fire. In the Ayurvedic Pharmacopoeia of India, the official single drug “Kutaja” is the dried stem bark of Holarrhena antidysenterica (Roth) A. DC., family Apocynaceae. Current botanical databases often treat this name as a synonym of Holarrhena pubescens Wall. ex G. Don, but the pharmacopoeial Ayurvedic drug identity remains the stem bark known as Kutaja, Kurchi, Kalinga, Shakra, or Vatsaka.

What sets Kutaja apart from ordinary astringent herbs is its combined Ayurvedic and phytochemical profile. Ayurveda classifies it as tikta and kashaya in taste, laghu and ruksha in quality, shita virya, and katu vipaka. Its actions include dipana, sangrahi, and kapha-pitta-shamana. This means Kutaja is not merely a stool-stopper; it is selected when the bowel needs drying, consolidation, digestive correction, and reduction of kapha-pitta type intestinal disturbance.

Phytochemical Profile: Alkaloids Behind the Classical Use

Kutaja bark is pharmacopoeially assayed for total alkaloids and is stated to contain conessine and related alkaloids. This alkaloid-rich identity is central to its specificity. Unlike tannin-dominant herbs that mainly tighten tissues by astringency, Kutaja combines a bitter-astringent Ayurvedic profile with a characteristic steroidal alkaloid fraction. Publications on Holarrhena list conessine along with related alkaloids such as holarrhimine, kurchicine, conimine, conessidine, isoconessimine, and other members of the same alkaloid group.

Modern pharmacological work on Holarrhena antidysenterica has described antidiarrhoeal activity in animal models and gut motility effects in isolated intestinal tissue. These findings fit the classical positioning of Kutaja for bowel disorders involving excessive liquidity, intestinal urgency, mucus, and disturbed motility, while still requiring proper diagnosis when infection, bleeding, dehydration, or systemic illness is present.

Clinical Use: Amoebic and Dysentery-Like Gut Patterns

A published Ancient Science of Life clinical report described 40 cases of amoebiasis and/or giardiasis and recorded the use of Kutaja bark in Entamoeba histolytica cyst passers. The report noted loose motions, flatulence, abdominal cramping, diminished appetite, mucus in stools, and a 70% good response among E. histolytica cyst passers treated with Kutaja bark. This supports the traditional positioning of Kutaja in intestinal amoebiasis-related bowel disturbance, but it does not make Kutaja a substitute for medical treatment in severe invasive amoebiasis.

In practical Ayurvedic use, Kutaja fits chronic or recurrent loose stool with kapha-pitta features: mucus, heaviness, foul smell, griping, incomplete evacuation, low appetite, and bowel looseness that worsens after unsuitable food. Its sangrahi role is especially relevant where the bowel is losing proper containment and the stool remains watery or semi-formed. Because it is ruksha and grahi in effect, it is not chosen casually for every stomach upset, nor for constipation-predominant conditions unless a practitioner identifies a specific indication.

Kutaja in Grahani and Chronic Loose Stool

Kutajarishta is listed in the Ayurvedic Formulary of India with Kutaja stem bark as the main ingredient, along with draksha, madhuka flowers, gambhari, guda, and dhataki. Its listed therapeutic uses include jvara, grahani, raktatisara, and agnimandya. This makes it especially relevant when loose stool is linked with weak digestion, post-infectious bowel irregularity, malabsorption-type patterns, or recurrent pitta-kapha intestinal disturbance.

For modern readers, grahani should not be reduced to a single biomedical diagnosis such as IBS-D. It is an Ayurvedic diagnostic category involving digestive fire, stool formation, appetite, strength, and the capacity of the gut to hold and transform food properly. Kutaja-based medicines may be considered within that framework, while persistent bowel change, blood, weight loss, fever, nighttime diarrhea, or dehydration needs medical evaluation.

Formulations and Dosage Context

Kutaja appears in several important Ayurvedic preparations, and the form is selected according to presentation, strength, chronicity, and the physician’s assessment. The Ayurvedic Pharmacopoeia lists Kutajarishta, Kutajavaleha, and Kutajaghana Vati as important formulations of Kutaja, while the Ayurvedic Formulary gives a standard adult dose of 12 to 24 ml for Kutajarishta. The single-drug monograph gives 20 to 30 g of the drug for decoction.

Kutaja decoction: This is the direct classical approach using the bark as a decoction. It is usually suited to clearly loose, watery, mucus-associated, or dysentery-like bowel patterns where a qualified practitioner has assessed the patient and ruled out emergency signs.

Kutajarishta: This fermented formulation is classically linked with grahani, raktatisara, agnimandya, and fever-associated digestive weakness. It is generally taken after meals in practice, but the exact schedule should follow practitioner advice, especially in patients with acidity, alcohol restriction, liver disease, pregnancy, or multiple medicines.

Kutajaghana Vati: This solid extract form is practical for travel and routine use when a physician wants the Kutaja action in tablet form. Because tablet strength varies by manufacturer, dose should be based on the product standard and a practitioner’s instruction rather than a fixed internet dosage.

Kutajavaleha: This semisolid preparation is one of the important Kutaja formulations listed in the pharmacopoeial monograph. It may be selected where the patient needs a more palatable or nourishing form, but it should still match the bowel pattern and digestive state.

Comparison With Pharmaceutical Alternatives

Kutaja belongs to Ayurvedic bowel management and should be understood in that context. In confirmed symptomatic amoebiasis, invasive intestinal disease, or suspected liver abscess, modern medical treatment commonly uses a tissue amoebicide such as metronidazole or tinidazole followed by a luminal agent. Kutaja may have a role in practitioner-supervised supportive Ayurvedic care, but severe amoebiasis is not a self-treatment situation.

Loperamide is a symptomatic anti-motility drug and is not a substitute for diagnosis in infectious diarrhea. It is contraindicated in acute dysentery with blood and fever, bacterial enterocolitis caused by invasive organisms, and certain colitis situations. Kutaja is also not meant to simply “block” diarrhea without diagnosis; its Ayurvedic use depends on the atisara, pravahika, grahani, agni, dosha, and strength context.

The most responsible comparison is therefore not “Kutaja versus antibiotic,” but “properly diagnosed infection versus Ayurvedic bowel pattern.” When diarrhea is mild, non-severe, and assessed as suitable for Ayurvedic management, Kutaja is a specific and classical choice. When diarrhea is bloody, febrile, dehydrating, persistent, recurrent without explanation, or associated with severe abdominal pain, investigation and medical treatment take priority.

Safety and When to Seek Care

Kutaja’s drying and consolidating action is useful only when the condition is suitable. It should not be used casually in infants, young children, pregnancy, frail elderly patients, immunocompromised patients, severe dehydration, high fever, blood in stool, suspected food poisoning, severe abdominal pain, or suspected amoebic liver involvement without medical supervision. Oral rehydration, diagnosis, and appropriate antimicrobial treatment may be essential in infectious diarrhea.

Medical disclaimer: Persistent or severe diarrhea, diarrhea with blood or fever, repeated vomiting, signs of dehydration, severe abdominal pain, weight loss, or symptoms in infants, children, elderly patients, pregnant women, or immunocompromised individuals requires medical evaluation. This educational content does not replace diagnosis or treatment by a qualified physician or Ayurvedic practitioner. Consult a qualified healthcare provider before using Kutaja or any herbal anti-diarrhoeal preparation.

References

1. Ayurvedic Pharmacopoeia of India
2. Powo (powo.science.kew.org)
3. Worldfloraonline (worldfloraonline.org)
4. Metabolic Diversity and Therapeutic Potential of Holarrhena pubescens: An Important Ethnomedicinal Plant (2020), PubMed Central
5. Ijpbs (ijpbs.com)
6. Ijpbs (ijpbs.com)
7. Researchgate (researchgate.net)
8. Veterinaryworld (veterinaryworld.org)
9. Pharmacological basis for the medicinal use of Holarrhena antidysenterica in gut motility disorders (2010), PubMed
10. Dravyaguna notes
11. Msdmanuals (msdmanuals.com)
12. CDC
13. NCBI
14. Idsociety (idsociety.org)
15. World Health Organization

Punarnava, the Ayurvedic name for Boerhavia diffusa Linn., has a firm place in kidney and fluid-retention practice because the classical record and modern pharmacology point in the same broad direction: moving urine, reducing shotha, and supporting renal tissues under monitored care. The Ayurvedic Pharmacopoeia of India describes the official drug as the dried, matured whole plant of Boerhavia diffusa, a trailing Nyctaginaceae herb found throughout India and collected after the rainy season.

The name Punarnava is traditionally understood as “that which becomes new again,” a fitting image for a plant that regenerates after dormancy. Its kidney-herb reputation is strongest when framed as a mutrala and shothahara dravya: it is used for fluid accumulation, swelling, urinary sluggishness, and the pandu-shotha pattern that often brings pallor, heaviness, and edema together in Ayurvedic assessment.

Classical Ayurvedic Profile

In the Ayurvedic Pharmacopoeia of India, Punarnava is presented as a whole-plant medicine with a specific taste-energy-action profile. Its madhura, tikta, and kashaya rasa, ruksha guna, ushna virya, and madhura vipaka support its classical use where kapha-related heaviness and vata-shleshma obstruction contribute to shotha and sluggish elimination.

Renal and Edema Support: Classical and Pharmacological Profile

The kidney-centered usefulness of Punarnava rests on several converging features: direct classical classification as mutrala, long use in shotha, plant constituents associated with antioxidant and anti-inflammatory actions, animal-model renal protection, and small human trials of Punarnava-containing formulations or procedures. This makes Punarnava a credible supportive herb for fluid-retention patterns, while still requiring diagnosis, dose selection, and monitoring.

Clinical Evidence for Kidney-Associated Formulations

A clinical comparative study in AYU evaluated a Punarnavadi compound in chronic renal failure patients over two months. The work included 67 patients in controlled clinical circumstances and compared allopathic control, Ayurvedic control, and Ayurvedic test groups. The Punarnava-containing compound was associated with improvements in quality-of-life symptoms such as breathlessness, weakness, and functional capacity, along with selected laboratory parameters including serum creatinine and serum calcium.

Another AYU clinical trial evaluated Gokshura-Punarnava Basti in diabetic nephropathy patients with microalbuminuria. This was a Punarnava-containing basti protocol rather than a simple oral root decoction, and its relevance lies in the broader Ayurvedic approach to early kidney involvement in diabetes, urinary albumin changes, and vata-kapha regulation.

These clinical references support Punarnava’s role as part of supervised renal and edema care, especially through classical compounds and procedures. They do not make Punarnava a substitute for nephrology care, prescription medicines, blood-pressure control, diabetes control, or laboratory monitoring.

Edema Applications in Ayurvedic Practice

In practice, Punarnava is selected when swelling and fluid retention appear with kapha-vata features such as heaviness, pitting edema, reduced urinary flow, sluggish digestion, pallor, or recurrent water accumulation. The herb is especially relevant where shotha and pandu overlap, which is why Punarnavadi Mandura remains an important formulation in anemia-with-edema presentations.

• Shotha with heaviness: Punarnava may be chosen when swelling is accompanied by kapha-type heaviness, sluggishness, and water retention.
• Pandu with swelling: Punarnavadi Mandura is traditionally used where pallor, weakness, and edema appear together, under professional supervision.
• Urinary sluggishness with fluid retention: Decoction-based use is appropriate only when the practitioner has assessed hydration, kidney function, blood pressure, and the cause of reduced urine flow.
• Diabetic kidney involvement: Punarnava-containing protocols belong in integrative care with glucose control, urine albumin monitoring, and physician supervision.
• Cardiac, renal, hepatic, or ascitic edema: These require medical evaluation; Punarnava should not be used to delay urgent treatment for breathlessness, severe swelling, falling urine output, jaundice, chest symptoms, or rapidly rising creatinine.

Forms and Dosing Guidance

The Ayurvedic Pharmacopoeia of India gives the dose of Punarnava as 20–30 g of the drug for decoction. Because the official drug is the whole plant and the clinical context may involve kidney disease, edema, anemia, diabetes, hypertension, or multiple medicines, dosing should be individualized by a qualified Ayurvedic practitioner or healthcare provider.

Whole-plant decoction: This is the most direct classical form for mutrala and shothahara use. It should be prepared and dosed according to classical pharmacy guidance, the patient’s constitution, fluid status, renal function, and concurrent medicines.

Punarnavadi Mandura: This iron-containing Ayurvedic formulation is used in pandu, shotha, and related presentations. It is not merely a “kidney tablet”; it is best suited when edema is accompanied by pallor, weakness, anemia-pattern assessment, or practitioner-selected indications.

Punarnavasava and Punarnavasaka Kvatha Churna: These are Punarnava-based classical formulations listed in official Ayurvedic sources. They are selected according to the patient’s digestive strength, edema pattern, associated symptoms, and need for decoction or fermented preparation.

Sukumara Ghrita and Shothaghna Lepa: These listed preparations show that Punarnava’s use extends beyond a single oral diuretic role. Internal ghrita use and external lepa use require matching the formulation to the disease stage, strength of the patient, and doṣic presentation.

Drug Interactions and Safety

Because Punarnava is used as a mutrala herb, it should be treated carefully in anyone taking prescription diuretics, lithium, antihypertensives, diabetes medicines, ACE inhibitors, ARBs, or medicines that affect electrolytes and kidney function. Kidney disease management requires regular monitoring of eGFR or creatinine, urine albumin or protein, blood pressure, hydration status, sodium, potassium, and other electrolytes.

Prescription diuretics: Combining Punarnava with furosemide, hydrochlorothiazide, spironolactone, torsemide, or similar medicines may increase urination, dehydration risk, blood-pressure changes, or electrolyte disturbance. Such combinations require physician supervision.

Lithium: Medicines and interventions that alter sodium balance, hydration, or diuresis can affect lithium handling. Punarnava should not be combined with lithium unless the prescribing physician is monitoring lithium levels, kidney function, and electrolytes.

Antihypertensive and kidney-protective medicines: Patients using ACE inhibitors, ARBs, beta blockers, calcium-channel blockers, or other blood-pressure medicines should monitor blood pressure and kidney labs when adding any mutrala herb.

Pregnancy, lactation, severe kidney disease, heart failure, ascites, and unexplained edema: These situations need direct care from a qualified clinician. Sudden swelling, breathlessness, reduced urine, blood in urine, severe weakness, high blood pressure, or rising creatinine should be treated as a medical priority.

For a broader Ayurvedic urinary-tract framework, see irritable bladder mutrakrichra Ayurvedic assessment and interstitial cystitis Ayurvedic bladder therapy.

Medical disclaimer: Kidney disease, edema, diabetes, hypertension, heart failure, liver disease, and urinary disorders require qualified medical assessment. Never use Punarnava as a substitute for prescribed kidney disease medication, dialysis planning, emergency care, or nephrology follow-up. Consult a qualified Ayurvedic practitioner and healthcare provider before starting Punarnava, especially if pregnant, lactating, managing a chronic condition, or taking medication.

References

1. Powo (powo.science.kew.org)
2. Ayurvedic Pharmacopoeia of India
3. Frontiersin (frontiersin.org)
4. Indianmedicine (indianmedicine.eldoc.ub.rug.nl)
5. Journalijar (journalijar.com)
6. Evaluation of the effect of Boerhavia diffusa on gentamicin-induced nephrotoxicity in rats (2015), PubMed Central
7. Rotenoids from Boerhaavia diffusa as potential anti-inflammatory agents (2013), PubMed
8. Neutralization of Inflammation by Inhibiting In vitro and In vivo Secretory Phospholipase A(2) by Ethanol Extract of Boerhaavia diffusa L (2017), PubMed Central
9. A clinical comparative study of the management of chronic renal failure with Punarnavadi compound (2010), PubMed
10. Clinical efficacy of Gokshura-Punarnava Basti in the management of microalbuminuria in diabetes mellitus (2012), PubMed
11. Upnrhm (upnrhm.gov.in)
12. NIDDK
13. Mayoclinic (mayoclinic.org)
14. Lithium therapy and its interactions (2020), PubMed Central
15. Mayoclinic (mayoclinic.org)
16. Jaims (jaims.in)
17. Constituents of the roots of Boerhaavia diffusa L. III. Identification of Ca2+ channel antagonistic compound from the methanol extract (1991), PubMed

Lodhra (Symplocos racemosa Roxb.) is a classical Ayurvedic bark drug with a strong place in gynecological practice, especially where astringent, cooling, kapha-pitta-balancing and tissue-supporting actions are required. In the PCOS context, its value should be understood as clinical potential rather than a stand-alone proven cure: Lodhra has classical authority for pradara-type reproductive complaints, a clear pharmacopoeial profile, and preliminary PCOS-relevant experimental work, while human single-herb PCOS trials remain limited.

The Ayurvedic Pharmacopoeia of India identifies Lodhra as the dried stem bark of Symplocos racemosa Roxb., family Symplocaceae. It is described as an evergreen tree found in plains and lower hills throughout India. The same monograph lists the bark taste as astringent and feebly bitter, and records its main constituents as alkaloids, especially loturine and colloturine, along with red colouring matter.

Ayurvedic Profile: Why Lodhra Enters PCOS Discussions

PCOS is a modern diagnostic category and does not correspond to one single classical disease name. Lodhra enters the discussion because its Ayurvedic profile overlaps with several patterns commonly assessed in PCOS care: kapha-pitta involvement, swelling or congestion, abnormal discharge, disturbed menstrual function, inflammatory skin tendency, and reproductive-channel imbalance. The Ayurvedic Pharmacopoeia lists Lodhra as kashaya rasa, laghu guna, sheeta virya, katu vipaka, and gives its karmas as chakshushya, grahi, and kaphapittanut.

Its classical use is strongest where astringency and kapha-pitta correction are appropriate. The pharmacopoeial therapeutic uses include shotha, atisara, netraroga, raktapitta, and pradara. This does not make Lodhra a universal PCOS herb. It is most rational in practitioner-guided protocols when the presentation includes kapha-pitta features, discharge, inflammatory tendency, heaviness, swelling, or bleeding-pattern disturbance rather than a purely dry, depleted, vata-dominant picture.

Phytochemical Profile: What Makes Lodhra Biologically Interesting

The pharmacopoeial identity of Lodhra is anchored in its alkaloids, especially loturine and colloturine. Broader phytochemical reviews of Symplocos racemosa also describe phenolic glycosides, triterpenoids such as betulinic acid and acetyloleanolic acid, and other plant compounds reported from the species or genus. These constituents make Lodhra biologically interesting for PCOS research because PCOS commonly involves reproductive-endocrine disturbance, inflammation, insulin resistance, and ovarian tissue changes.

Clinical and Experimental Evidence: What Has Actually Been Done

Human data for Lodhra as a single herb in PCOS are sparse. The strongest PCOS-specific material is experimental and formulation-based. A rat study in Journal of Coastal Life Medicine evaluated Symplocos racemosa in letrozole-induced PCOS. The intervention used low, medium, and high doses after PCOS induction and recorded reduction of elevated testosterone, improvement in estrogen and progesterone parameters, cholesterol changes, and recovery of ovarian and uterine tissue features at the mid and high doses. This supports a PCOS-relevant anti-androgen and ovarian-tissue rationale, but it does not establish a direct human treatment protocol.

An older Journal of Ethnopharmacology paper evaluated aqueous Symplocos racemosa extract in immature female rats and reported changes in gonadotropin release, including FSH and LH, along with ovarian histology observations. This is relevant to follicular maturation and hypothalamic-pituitary-ovarian axis discussion, but it remains preclinical.

A separate experimental study assessed “DXB-2030,” a polyherbal formulation containing Trigonella foenum-graecum, Aloe vera, Sphaeranthus indicus, Nardostachys jatamansi, and Symplocos racemosa, in testosterone-propionate-induced PCOS rats. The formulation was associated with better GLUT4 expression, lower body weight, lower testosterone, improved glucose tolerance measures, and fewer cystic follicles. This is useful formulation evidence, but it cannot isolate Lodhra’s individual contribution.

How Lodhra Fits Into an Ayurvedic PCOS Plan

Lodhra is best viewed as a targeted herb within a larger Ayurvedic assessment rather than a generic hormone-balancing supplement. A practitioner may consider it when PCOS presents with kapha-pitta features such as heaviness, inflammatory acne tendency, abnormal discharge, swelling, or bleeding disturbance. Where the presentation is dominated by depletion, severe dryness, marked vata aggravation, or very scanty cycles without kapha-pitta signs, Lodhra may not be the central herb.

Modern PCOS care also requires diagnosis and monitoring. Clinical diagnosis commonly uses combinations of androgen excess, ovulatory dysfunction, and polycystic ovarian morphology after excluding other causes. Lifestyle, weight management when relevant, metabolic screening, cycle history, androgen symptoms, fertility goals, and psychological wellbeing all remain part of comprehensive care. Lodhra, when used, should sit inside this broader framework rather than replace medical evaluation.

Dosage and Preparation

The Ayurvedic Pharmacopoeia of India lists the dose of Lodhra as 3–5 g of the drug in powder form and 20–30 g of the drug for decoction. These figures are pharmacopoeial reference doses, not a PCOS prescription. In actual practice, dose, duration, anupana, and combinations depend on prakriti, agni, bowel pattern, menstrual history, bleeding or discharge pattern, metabolic status, current medicines, and fertility goals.

For PCOS, Lodhra should not be used casually for months without review. Menstrual cycle pattern, pregnancy possibility, acne or hirsutism, weight changes, glucose and insulin-related markers, thyroid and prolactin status when indicated, and ultrasound findings may all affect the treatment plan. Practitioner-guided use is especially important if Lodhra is combined with other herbs such as Ashoka, Shatavari, Kanchanara, Guduchi, Triphala, or formulation-based approaches.

Safety, Pregnancy, and Lactation Considerations

Lodhra has astringent and grahi qualities, so self-use is not advisable during pregnancy or while trying to manage an uncertain missed period. Anyone using Lodhra for PCOS should stop self-directed use and consult a qualified practitioner or healthcare provider if pregnancy is suspected or confirmed. Safety during breastfeeding is also not well established for unsupervised use, so lactating mothers should use it only under professional guidance.

Medical disclaimer: PCOS requires proper medical diagnosis and monitoring. This article is educational and does not diagnose, treat, or replace care from a gynecologist, endocrinologist, qualified Ayurvedic physician, or other healthcare provider. Consult a qualified practitioner before using Lodhra, especially if pregnant, trying to conceive, breastfeeding, taking hormonal medicines, using fertility treatment, managing diabetes or thyroid disease, or experiencing abnormal bleeding.

References

1. Ayurvedic Pharmacopoeia of India
2. A comprehensive analysis on Symplocos racemosa Roxb.: Traditional uses, botany, phytochemistry and pharmacological activities (2016), PubMed
3. Scialert (scialert.net)
4. Scialert (scialert.net)
5. Researchgate (researchgate.net)
6. Effect of Symplocos racemosa Roxb. on gonadotropin release in immature female rats and ovarian histology (2004), PubMed
7. Effect of “DXB-2030,” a Polyherbal Formulation, on Experimental Polycystic Ovary Syndrome Associated with Hyperandrogenism (2019), PubMed Central
8. Academic (academic.oup.com)
9. Academic (academic.oup.com)

Tamra Bhasma is a classical Ayurvedic herbo-metallic preparation made from copper after purification and incineration procedures such as shodhana, bhavana, marana and, in many protocols, amritikarana. Its scientific interest lies in the fact that classical processing can change raw metallic copper into a fine, calcined material with different phase composition, crystallite size, aggregation pattern and elemental profile from the starting metal.

The nanomedicine view of Tamra Bhasma is useful when it is kept precise. Published analytical work does not support treating every product sold as “Tamra Bhasma” as chemically identical. Some characterized samples have matched copper oxide, some have shown copper sulfide phases, and some have shown nanocrystalline domains that exist within larger agglomerates. For this reason, the batch, preparation method and quality-control profile matter as much as the classical name.

Analytical Profile: Particle Size, Phase and Composition

Modern characterization has used tools such as X-ray diffraction, scanning electron microscopy, energy-dispersive X-ray analysis, X-ray photoelectron spectroscopy, infrared or FTIR spectroscopy, thermogravimetry, particle-size distribution and elemental analysis. Together, these tools separate three questions that are often confused: whether the copper is still metallic, what chemical phase the final product contains, and whether the powder contains nanoscale crystallites or larger agglomerated particles.

Why the Nanomedicine Lens Matters

The nanocrystalline interpretation helps explain why bhasma is not simply equivalent to a piece of raw metal. Repeated heating, quenching, levigation and incineration can reduce particle or crystallite size, change crystal phase, increase surface area and alter how the material behaves in biological fluids. At the same time, nanoscale structure does not by itself prove safety or therapeutic effect; safety depends on correct preparation, dose, adjuvant, patient selection and monitoring.

For Tamra Bhasma, the most accurate modern language is “processed copper-based bhasma with nanoscale crystallites in some characterized samples.” This is more reliable than broad claims that all Tamra Bhasma particles are uniformly 20–120 nm or that all products have the same copper oxide chemistry.

Hepatotoxicity: The Critical Safety Question

Copper is an essential trace element, but excess copper exposure can injure the liver. Adult nutritional references commonly place the recommended copper intake at 900 mcg per day and the adult upper intake level at 10 mg per day, with liver damage as the critical adverse endpoint for excess intake. Tamra Bhasma is therefore not comparable to casual dietary copper intake; it is a concentrated classical medicine that requires professional selection and supervision.

Available animal safety data place the risk in three linked areas: whether the copper was purified, whether amritikarana was performed, and how high the dose was. In a 45-day rat evaluation, Tamra Bhasma prepared from unpurified copper produced pathological changes even at the therapeutic-equivalent dose, while the product prepared from purified copper remained safe within the tested protocol up to five times the therapeutic-equivalent dose. In a separate 28-day rat comparison, Tamra Bhasma with and without amritikarana produced no signs of toxicity at therapeutic-equivalent and five-times therapeutic-equivalent doses, while ten-times therapeutic-equivalent dosing produced mild toxicity in organs including liver, kidney, heart and thymus; the non-amritikarana sample showed greater toxicity.

The Role of Classical Purification in Reducing Risk

Classical processing is central to the safety discussion. In a documented standard manufacturing procedure, copper pieces were heated to a red-hot stage and quenched repeatedly in media including sesame oil, buttermilk, cow urine, sour gruel and horse gram decoction during samanya shodhana. A further vishesha shodhana step involved processing the already purified copper in cow urine. These steps precede marana and are not optional when Tamra Bhasma is intended for internal use.

Marana then converts the purified copper through incineration and levigation procedures. Some protocols include purified sulfur, kajjali and lemon juice; amritikarana may follow as a post-incineration refinement. The available comparative toxicity work aligns with the classical insistence that ashuddha or improperly processed Tamra is unsafe and that shodhana and amritikarana are risk-reducing steps rather than cosmetic processing.

Therapeutic Applications and Classical Dosing

Tamra Bhasma is described in Ayurvedic literature and related Rasashastra-oriented sources for selected conditions such as udara, pandu, shvasa and amlapitta, and it is also discussed in relation to disorders of the liver and spleen, abdominal pain, loss of appetite and anemia. These indications belong to physician-directed Ayurvedic practice and should not be converted into self-treatment claims.

A cited classical dosing guideline used in toxicology dose conversion gives Tamra Bhasma as 30 mg twice daily, with honey used as the adjuvant in the animal protocol. Other dose ranges in commercial summaries are less reliable unless tied to a specific classical text, formulation and patient context. The safer practical rule is that Tamra Bhasma should be taken only when prescribed by a qualified Ayurvedic physician and only in the dose, duration and anupana selected for the individual.

Practical Quality Checklist for Safe Discussion with a Practitioner

Because products differ, a responsible discussion should include whether the material was prepared from shodhita copper, whether marana and amritikarana were documented, whether the batch passed classical bhasma tests, and whether modern batch testing includes phase identification, particle or crystallite characterization, elemental profile and screening for toxic contaminants. Patients should also ask whether baseline and follow-up liver and kidney function tests are appropriate for their condition and course length.

Unverified, home-prepared, marketplace-grade or unlabeled metallic preparations should not be used internally. Even a properly prepared Tamra Bhasma is still a potent herbo-metallic medicine, not a wellness supplement. It is especially inappropriate for self-use in pregnancy, liver disease, kidney disease, Wilson’s disease, unexplained anemia, children, or anyone taking regular medication unless supervised by qualified clinicians.

Bottom Line

Tamra Bhasma is a legitimate subject for modern nanomedicine-style analysis because some characterized preparations contain nanoscale crystallites and chemically transformed copper phases. The strongest verified safety message is not that copper bhasma is automatically safe, but that correct shodhana, marana, amritikarana, batch testing, dose control and clinical monitoring are essential to reduce risk.

Medical disclaimer: Tamra Bhasma is a metallic Ayurvedic preparation requiring qualified prescription and monitoring. Self-administration of metallic bhasma preparations is not safe or appropriate. Consult a qualified Ayurvedic practitioner and a healthcare provider before using any bhasma, especially if pregnant, nursing, managing liver, kidney, neurological or metabolic disease, or taking medication.

References

1. Researchgate (researchgate.net)
2. Library (library.ncl.res.in)
3. Researchgate (researchgate.net)
4. NCBI
5. NCCIH
6. Ayush (ayush.delhi.gov.in)
7. Researchgate (researchgate.net)
8. Researchgate (researchgate.net)
9. Ayurvedic Pharmacopoeia of India
10. Ayurvedic Pharmacopoeia of India

In Ayurveda, stanya means breast milk, and Kaumarabhritya places it at the center of newborn nourishment. The first secretion after birth—the early, thick milk known in modern medicine as colostrum—is described here as prathama stanya, “first stanya,” for clarity. Ayurveda values breast milk as life-supporting, nourishing, strength-promoting, and supportive of ojas, the subtle principle associated with vitality and resilience.

Colostrum is a small-volume, highly concentrated early milk produced during the first days after birth. It is naturally suited to the newborn’s small stomach and immature digestive system. Compared with mature milk, it is richer in protective proteins, secretory immunoglobulin A, lactoferrin, leukocytes, human milk oligosaccharides, and growth factors, while its fat and lactose profile changes as lactation progresses.

Immunological Mechanisms: Why Colostrum Is Irreplaceable

Colostrum protects mainly at the mucosal surfaces of the newborn’s mouth, throat, and intestine. In humans, the main transfer of systemic passive immunity occurs before birth through maternal IgG crossing the placenta. After birth, the antibodies in breast milk—especially secretory IgA—primarily coat and protect the gut lining, help shape early microbial colonization, and support immune tolerance during a vulnerable period of adaptation.

This makes early breastfeeding deeply important even without the claim that human newborns absorb large quantities of intact milk antibodies into the bloodstream. The first feed helps deliver mucosal protection, stimulates digestion, supports bonding, and encourages the hormonal rhythm of lactation. Current neonatal guidance recommends early, uninterrupted skin-to-skin contact and initiation of breastfeeding within the first hour after birth whenever mother and baby are clinically stable.

Why Colostrum Should Not Be Discarded

Discarding colostrum because it appears thick, yellow, or scanty is contrary to both sound newborn care and the Ayurvedic respect for stanya. The first milk is not “dirty” or inferior; its color and density reflect its concentrated protective composition. Ayurveda’s emphasis on nourishing the newborn with mother’s milk is consistent with the practical priority of giving colostrum early.

Pre-lacteal feeds such as honey, sugar water, plain water, animal milk, or formula should not be used before breastfeeding unless there is a clear medical indication. Such feeds can interfere with early suckling, delay breastfeeding establishment, and increase the chance of avoidable exposure to contaminants. The safest general principle is immediate skin-to-skin contact and early breastfeeding support from trained birth attendants, pediatricians, and lactation consultants.

Classical Navajata Paricharya and First Feeding Rituals

Classical newborn-care passages include ritual elements around jatakarma, including auspicious touch, mantra, and in some traditions small oral offerings involving honey, ghee, or gold preparations before breastfeeding. These passages belong to a historical ritual context and should not be applied casually in modern newborn care.

For present-day practice, the verified and safe priority is to place the clinically stable newborn skin-to-skin and begin breastfeeding within the first hour. Ritual intention may be preserved through blessing, mantra, prayer, or gentle touch without giving unsafe oral substances. Honey should not be given to infants under 12 months because of the risk of infant botulism.

Ayurvedic texts also describe the mother’s sight, touch, holding, and affectionate attention toward the baby as supportive of milk flow. This harmonizes well with the practical value of uninterrupted mother-baby contact, calm surroundings, and skilled help with latch during the first hours after birth.

Maternal Nutrition for Healthy Stanya

Ayurveda places strong emphasis on garbhini paricharya, the diet and lifestyle care of pregnancy. The pregnant woman’s properly digested food is understood to nourish the mother, support the fetus, and help prepare the formation of breast milk. Classical guidance favors foods that are wholesome, palatable, nourishing, moist, and easy to digest, with milk and ghee appearing prominently in many traditional pregnancy diet descriptions.

Modern nutritional understanding also treats human milk as dynamic. Its composition changes with stage of lactation, infant needs, maternal diet, and maternal nutrient status. Nutrients such as fatty acids and several vitamins can be influenced by the mother’s intake, so pregnancy and lactation nutrition should be planned with qualified medical guidance, especially when there is anemia, vitamin D deficiency, thyroid disease, diabetes, digestive illness, or use of medication.

Shatavari (Asparagus racemosus) is a classical Ayurvedic herb associated with lactation support. The Ayurvedic Pharmacopoeia of India describes Shatavari root as madhura and tikta in rasa, guru and snigdha in guna, shita in virya, madhura in vipaka, and includes stanyakara action with use in stanya kshaya. The crude-drug dose listed in the pharmacopoeia is 3–6 grams, but pregnancy and lactation use should be supervised by a qualified Ayurvedic practitioner or healthcare provider.

Bovine Colostrum as a Supplement: A Separate Topic

Bovine colostrum is the first milk produced by a cow after calving. It contains immunoglobulins, lactoferrin, antimicrobial peptides, growth factors, proteins, fats, carbohydrates, vitamins, and minerals. Adult supplement use of bovine colostrum is a separate subject from human newborn feeding and should never be confused with the baby’s need for the mother’s own colostrum.

Some Ayurvedic dietetic discussions refer to cow colostrum as piyusha and describe it as heavy, nourishing, and strength-supporting. This belongs to food and dietetics, not to the management of a human newborn’s first feed. A newborn should receive mother’s colostrum whenever breastfeeding is possible; when breastfeeding is medically difficult, care should be guided by pediatric and lactation professionals.

Bovine colostrum supplements may not be suitable for people with dairy allergy, milk-protein intolerance, certain immune conditions, or those using complex medication regimens. They should be used only with professional guidance, particularly for children, pregnant women, lactating mothers, older adults, and anyone with chronic illness.

Medical disclaimer: This content is for educational purposes only. Breastfeeding decisions, neonatal care, lactation problems, delayed milk production, infant jaundice, prematurity, low birth weight, or feeding difficulty should be managed with a pediatrician and certified lactation consultant. Consult a qualified Ayurvedic practitioner or healthcare provider before using herbs, supplements, or traditional protocols during pregnancy or lactation. Do not give honey to infants under 12 months.

References

1. Charaka Samhita — Stanya
2. Charaka Samhita — Stanya
3. E-cep (e-cep.org)
4. Mdpi (mdpi.com)
5. World Health Organization
6. World Health Organization
7. Mdpi (mdpi.com)
8. Prelacteal feeding practice and its associated factors among mothers of children age less than 24 months old in Southern Ethiopia (2019), PubMed Central
9. Canada (canada.ca)
10. Books (books.kdpublications.in)
11. Books (books.kdpublications.in)
12. Charaka Samhita — Prenatal care (garbhini paricharya
13. Frontiersin (frontiersin.org)
14. Ayurvedic Pharmacopoeia of India
15. Bovine Colostrum: Its Constituents and Uses (2021), PubMed Central
16. Jaims (jaims.in)

Bakuchi, botanically Psoralea corylifolia Linn., has a credible but carefully bounded place in Ayurvedic vitiligo care. In Ayurveda, vitiligo-like depigmentation is discussed as shvitra or kilasa within the broader kushtha framework, and Bakuchi is classically listed among substances used for shvitra. Its modern relevance comes from its naturally occurring photosensitizing constituents, especially psoralen and isopsoralen, which belong to the same broad furocoumarin family used in psoralen-based photochemotherapy.

This does not make Bakuchi a simple home remedy. Vitiligo is an acquired depigmenting condition involving loss or dysfunction of melanocytes, and it commonly has an autoimmune background. Bakuchi can be useful only when the patient, the type of lesion, the method of application, the light exposure, and the safety monitoring are handled correctly. The best candidates are usually those with limited or relatively recent patches, preserved hair-follicle pigment, and access to supervised light exposure. Long-standing, extensive, confluent, acral, or hair-whitened lesions are harder to repigment.

Classical Dravyaguna and Shvitra Indications

The Ayurvedic Pharmacopoeia of India identifies Bakuchi as the dry ripe fruit of Psoralea corylifolia Linn. and lists the Sanskrit names Avalguja and Somaraji. Its documented constituents include essential oil, fixed oil, psoralen, psoralidin, isopsoralen, and bakuchiol. The same monograph gives its rasa as katu and tikta, guna as ruksha, virya as shita, and vipaka as katu. Its listed therapeutic uses include kushtha and shvitra, with classical formulations such as Somaraji Taila and Avalgujadi Lepa.

Psoralen Mechanisms and Controlled Light Exposure

Psoralens are photosensitizing furocoumarins. In medical PUVA therapy, a psoralen compound is paired with UVA exposure under controlled dosing. This pairing is important: the active principle is not simply “taking Bakuchi” or “putting oil on a patch,” but the carefully managed interaction between photosensitizer, skin, lesion type, and ultraviolet light.

Repigmentation in vitiligo commonly begins from remaining melanocyte reservoirs, especially around hair follicles. This is why tiny dark dots within a pale patch, known clinically as perifollicular repigmentation, are a favorable sign. Areas with strong follicular reservoirs, such as the face and neck, usually respond better than hands, feet, fingertips, toes, elbows, knees, and bony prominences. Completely white lesions with white hair are more difficult because the local pigment reservoir may be depleted.

Human Clinical Evidence: What Is Solid and What Is Still Preliminary

The strongest contemporary benchmark for vitiligo repigmentation is dermatologist-supervised phototherapy, especially narrowband UVB. Psoralen-based therapy has a long medical history, but it requires accurate dosing and monitoring because excessive exposure can cause erythema, swelling, blistering, itching, nausea, and other adverse reactions. Bakuchi sits between classical practice and modern phototherapy: its rationale is strong, but the human trial base for Bakuchi preparations remains much smaller than the evidence base for medical phototherapy.

Clinical Use: Supervision Rather Than Self-Treatment

Bakuchi-based vitiligo care should be planned by a qualified Ayurvedic practitioner and coordinated with a dermatologist when phototherapy, spreading disease, autoimmune disease, children, pregnancy, liver disease, or photosensitizing medicines are involved. The API monograph lists an adult powder dose range, but a pharmacopoeial dose is not a self-treatment instruction; the appropriate form, dose, anupana, duration, and external application depend on constitution, lesion activity, digestive strength, concurrent medicines, and skin reactivity.

• Internal use: Use only under professional supervision, especially because oral Psoralea corylifolia preparations have been associated with liver injury in case literature.
• Topical use: Prefer standardized, pharmacy-prepared formulations such as classical taila or lepa rather than homemade concentrated extracts.
• Patch testing: A small test area should be observed before broader use, because irritation, burning, itching, erythema, and blistering can occur.
• Light exposure: Bakuchi should not be combined with uncontrolled sunbathing or unsupervised UV devices. The goal is mild, controlled stimulation, not inflammation or blistering.
• Stopping signs: Burning pain, swelling, blisters, marked redness, worsening itch, dark crusting, nausea, jaundice, dark urine, or unusual fatigue require stopping the product and seeking medical advice.

Adjunct Ayurvedic Support Around Bakuchi

Classical shvitra care is not limited to stimulating pigment locally. Charaka describes broader kushtha treatment principles, including shodhana where appropriate, use of kushthaghna medicines, and special emphasis on Khadira in skin-disease contexts. In shvitra, the text specifically places purgation and sunlight within the therapeutic sequence and also mentions external applications containing Avalguja or Bakuchi in selected formulations.

For this reason, a responsible Ayurvedic plan may include digestive correction, bowel regulation, carefully selected shodhana, Khadira-based preparations, classical ghrita or lepa, and diet correction before or alongside Bakuchi. These are not interchangeable add-ons; they are chosen according to dosha, dhatu involvement, chronicity, strength of the patient, lesion activity, and tolerance of the skin.

Dietary Triggers and Viruddha Ahara

Ayurvedic texts connect kushtha and shvitra with unsuitable diet and conduct, especially incompatible food and drink, excessive heavy or sour patterns, and repeated use of foods that disturb digestion and dosha balance. Charaka lists antagonistic foods and drinks along with items such as curd, fish, sesame, excessive salty and sour intake, black gram, radish, milk, and sugarcane products in the etiological discussion of kushtha.

In practice, this does not mean that diet alone repigments vitiligo. It means that dietary correction supports the larger treatment plan by reducing avoidable aggravating factors. A practitioner may restrict incompatible combinations, excessive sour and salty foods, heavy curd-based meals, and poorly digested food patterns, especially when lesions are active or inflammatory.

Realistic Repigmentation Timelines

Vitiligo repigmentation is gradual. Early improvement often appears as small perifollicular pigment dots inside a pale patch before the border contracts or the whole patch blends with surrounding skin. With phototherapy, meaningful assessment usually requires months, and longer supervised courses often produce better outcomes than short, irregular attempts. Face and neck lesions tend to respond best; trunk lesions are intermediate; extremities and hands-feet are more resistant.

Ayurveda also recognizes prognosis differences. Charaka describes lesions that are thin, pale, not long-standing, not associated with red hair, and separated by unaffected skin as more favorable. Confluent patches, many lesions, reddish hair involvement, and disease present for more than a year are described as more difficult. This classical view aligns with the practical need for early, consistent, supervised care rather than delayed experimentation.

Safety and Prudent Use

Bakuchi contains active photosensitizing compounds and should be treated with the same respect given to other light-reactive therapies. Potential adverse effects include irritation, itching, erythema, blistering, hyperpigmentation of surrounding skin, gastrointestinal discomfort, liver enzyme elevation, and rare serious liver injury. Risk increases with concentrated extracts, excessive oral dosing, prolonged unsupervised use, strong sunlight, UV devices, liver disease, and concurrent photosensitizing medicines.

Medical disclaimer: This article is for educational purposes only. Vitiligo is a medical condition that may require dermatological evaluation, autoimmune screening, and supervised phototherapy. Do not self-treat with Bakuchi, psoralen-containing herbs, UV devices, or prolonged sun exposure. Consult a qualified Ayurvedic practitioner and a healthcare provider before using herbs, supplements, detoxification procedures, or topical protocols, especially during pregnancy, while breastfeeding, in children, with liver disease, with photosensitivity disorders, or while taking medication.

References

1. Ayurvedic Pharmacopoeia of India
2. Charaka Samhita — Kushtha Chikitsa
3. NCBI
4. Link (link.springer.com)
5. NCBI
6. Onlinelibrary (onlinelibrary.wiley.com)
7. Phototherapy for Vitiligo: A Systematic Review and Meta-analysis (2017), PubMed
8. Dermnetnz (dermnetnz.org)
9. Dermnetnz (dermnetnz.org)
10. Trends in Regenerative Medicine: Repigmentation in Vitiligo Through Melanocyte Stem Cell Mobilization (2017), PubMed Central
11. Tandfonline (tandfonline.com)
12. Jintegrativederm (jintegrativederm.org)
13. Clinical evaluation of the efficacy of Shvitrahara kashaya and lepa in vitiligo (2011), PubMed
14. Dovepress (dovepress.com)
15. Tandfonline (tandfonline.com)

Trikatu is the classical “three pungents” combination of Maricha (black pepper, Piper nigrum fruit), Pippali (long pepper, Piper longum fruit), and Shunthi (dry ginger, Zingiber officinale rhizome), traditionally prepared in equal parts. In Ayurveda it is used as a deepana-pachana formulation: it supports appetite, kindles agni, helps digest ama, and is especially suited to kapha-dominant sluggishness, heaviness, coldness, and mucus tendency.

Modern pharmacokinetic work gives a useful explanation for one reason Trikatu became famous as a yogavahi-style helper in formulations: its pepper components contain piperine, and piperine can alter intestinal absorption and first-pass handling of some substances. This makes Trikatu valuable, but it also means it should not be treated as an ordinary kitchen spice when used in concentrated doses or alongside medicines with narrow safety margins.

Mechanism of Bioavailability Enhancement: Three Main Pathways

Piperine is the principal pungent alkaloid of black pepper and is also present in long pepper. It has been characterized as an inhibitor of human P-glycoprotein and CYP3A4, two systems that strongly influence oral drug disposition. P-glycoprotein can pump absorbed compounds back toward the intestinal lumen, while CYP3A4 contributes to intestinal and hepatic metabolism of many medicines and phytochemicals. Piperine also acts on TRPV1, the pungency-sensing ion channel associated with the “hot” sensory action of pepper.

For curcumin, a classic human pharmacokinetic trial found that 20 mg piperine given with 2 g curcumin markedly increased measurable curcumin exposure. This finding is often used to explain why pepper extracts are added to turmeric and curcumin products. The same principle should be handled carefully: a substance that increases exposure to one poorly absorbed compound may also alter exposure to selected medicines.

Current Drug-Interaction Perspective

The practical issue is not that every pinch of pepper creates a drug interaction. The concern is concentrated piperine, repeated use, extract-strength products, or Trikatu used medicinally in people taking medicines affected by CYP3A4, P-glycoprotein, CYP2C9, or clotting pathways. Human and modeling data indicate that piperine-containing preparations can affect selected probe drugs and CYP3A4-substrate exposure, while not every clinical experiment shows a large effect under every dosing condition. For household culinary use the concern is lower; for therapeutic churna, capsules, or standardized piperine extracts the concern is higher.

Trikatu’s Three Components Are Not Interchangeable

Black pepper extract is not the same as classical Trikatu. Maricha supplies piperine-rich pungency and strong kapha-vata-reducing heat. Pippali adds a related but distinct long-pepper profile, traditionally valued in kasa, shvasa, agnimandya, and rasayana contexts when used properly. Shunthi brings the dry-ginger action: warming, digestive, kapha-vata-pacifying, and more suitable than fresh ginger in many kapha-ama patterns.

The phytochemical profile also differs. Long pepper contains piperine and other amide constituents, including piperlongumine, a compound investigated mainly in preclinical pharmacology. Dry ginger contains gingerols and shogaols, with shogaols becoming more prominent in dried or heated ginger. Classical Trikatu should therefore be understood as a three-drug formulation, not merely as “piperine powder.”

Ayurvedic Use: Deepana, Pachana, Kapha-Vata Support

In Ayurvedic practice, Trikatu is best matched to cold, heavy, sluggish digestion; coated tongue with ama tendency; reduced appetite; kapha-type congestion; and vata-kapha obstruction where warmth, sharpness, and scraping action are desired. Its katu rasa, ushna tendency, and tikshna quality make it inappropriate for many pitta-dominant presentations unless carefully balanced by an experienced practitioner.

Its role in formulas is also important. Trikatu appears widely as a supporting combination because it can sharpen the digestive and assimilative action of a preparation. This is the classical counterpart to its modern bioenhancer reputation: it is not only a “pepper additive,” but a digestive-fire correcting group that changes how a formulation is received by the body.

Dosage Guidance and Practical Use

Common adult churna use is conservative, often around 500 mg to 1.5 g once or twice daily, usually with honey, warm water, or as directed by a qualified Ayurvedic practitioner. Sensitive individuals may require smaller amounts, and those with heat, acidity, gastritis, ulcers, loose stools with burning, or bleeding tendency may not be suitable candidates.

For deliberate nutraceutical bioavailability enhancement, standardized piperine doses in the 5-20 mg range appear in human trials and product practice, but that is not automatically equivalent to taking classical Trikatu. Trikatu contains three botanicals with their own actions, and its use should be based on agni, dosha, disease state, season, strength, and concurrent medicines.

For respiratory or kapha-metabolic use, Trikatu is traditionally paired with honey or warm water when kapha is prominent. Higher or repeated dosing is more likely to provoke pitta symptoms and more likely to raise interaction concerns. A short, practitioner-guided course is preferable to long unsupervised daily use.

Contraindications and Special Populations

Trikatu should generally be avoided in active peptic ulcer disease, significant acid reflux with burning, inflammatory bowel flare, bleeding tendency, marked pitta aggravation, and unexplained abdominal pain. It may cause burning, throat irritation, sweating, loose stools, or heat symptoms when the dose or patient selection is wrong.

Pregnant women should not use medicinal Trikatu unless specifically prescribed by a qualified clinician. People who are breastfeeding, elderly, taking long-term prescription medicines, preparing for surgery, using anticoagulants or antiplatelet drugs, or living with liver, kidney, transplant, seizure, cardiac, or autoimmune conditions should consult a qualified practitioner or healthcare provider before using Trikatu medicinally.

Medical disclaimer: This content is for educational purposes only and does not constitute medical advice. Trikatu and piperine-containing products may interact with medicines. Consult a qualified Ayurvedic practitioner, physician, or pharmacist before using Trikatu therapeutically, especially if you take prescription medicines or have a diagnosed medical condition.

References

1. Ijrap (ijrap.net)
2. Ayurvedic Pharmacopoeia of India
3. Ayurvedic Pharmacopoeia of India
4. Pubchem (pubchem.ncbi.nlm.nih.gov)
5. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4 (2002), PubMed
6. A distinct structural mechanism underlies TRPV1 activation by piperine (2019), PubMed Central
7. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers (1998), PubMed
8. Hero (hero.epa.gov)
9. The effect of piperine on midazolam plasma concentration in healthy volunteers, a research on the CYP3A-involving metabolism (2014), PubMed Central
10. Mdpi (mdpi.com)
11. FDA
12. FDA
13. Effects of Oral Ginger Supplementation on the INR (2019), PubMed Central
14. Health (health.ucsd.edu)
15. Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent (2020), PubMed
16. NCBI
17. 1mg (1mg.com)
18. Easyayurveda (easyayurveda.com)

Nausadar, also written as Navasadara, Naushadar, Navasara or Navasadar, occupies a careful place in Ayurvedic mineral pharmacy. It is not an everyday kitchen salt, not a general wellness supplement, and not a substance for casual self-use. Nausadar Ayurveda safety depends on correct identity, proper purification or documented pharmaceutical quality, measured dose, appropriate indication, and exclusion of patients in whom ammonium chloride can disturb acid-base balance.

Chemically, Nausadar is ammonium chloride, NH₄Cl. In Rasa Shastra teaching it is classed among the Sadharana Rasa mineral substances and is associated with names such as Navasadara and Chullika Lavana. This is a more accurate classification than treating it simply as a kshara or as a common household salt. Classical and later Ayurvedic pharmacy discusses it mainly as a processed mineral ingredient used in selected compound preparations, not as a stand-alone daily remedy.

Classical Identity and Processing

The Ayurvedic Formulary of India records a purification method for Navasara with reference to Rasatarangini, Taranga 14, verses 3-4. The method uses one part Navasara and three parts water: the material is dissolved, filtered, and then heated until the water evaporates. The practical purpose of this process is to obtain a cleaner crystalline material by solution, filtration, and recrystallization-like recovery, separating visible and insoluble impurities before medicinal use.

This correction matters for safety. The shodhana method described in the official formulary is not simply a ceremonial step and should not be replaced by using crude market-grade Nausadar in home preparations. At the same time, it should not be described as a guaranteed removal of every possible contaminant. For a modern product, identity testing, purity testing, heavy-metal limits, GMP manufacture, clear labeling, and practitioner supervision remain essential.

Modern Pharmacology of Ammonium Chloride

Modern pharmacology describes ammonium chloride as an acidifying salt. Prescription labeling for ammonium chloride injection identifies it as an electrolyte replenisher and systemic acidifier, and explains that its therapeutic effect depends on liver conversion of ammonia to urea and kidney handling of acid-base balance. This mechanism explains why the same substance may be useful in carefully selected medical contexts but unsafe in patients with impaired hepatic or renal function.

Drug references also describe ammonium chloride as an expectorant. Its expectorant action is attributed to irritation of the bronchial mucosa, causing increased respiratory tract fluid so that thick secretions are easier to expel. This aligns with the Ayurvedic description of Navasadara as kapha-nissaraka, a substance used in selected contexts where Kapha obstruction and thick phlegm are central features.

The safety boundary is equally clear. Overdose or inappropriate administration of ammonium chloride can produce serious metabolic acidosis, confusion, disorientation, and coma. Because the liver and kidneys are central to its handling, Nausadar-containing preparations should be avoided in severe liver disease, severe kidney disease, known metabolic acidosis, and situations where medical monitoring is not available.

Use Contexts in Ayurveda

In Ayurvedic language, Navasadara is described in connection with deepana, ruchya, and kapha-nissaraka actions. These terms support its traditional placement in selected digestive and respiratory formulations. They should not be stretched into broad claims that Nausadar treats all coughs, all low-acid digestive states, urinary infections, kidney stones, or chronic respiratory disease.

For productive cough with thick Kapha-type mucus, Nausadar may appear in practitioner-selected compound preparations where the dose is small and balanced with other ingredients. It should not be substituted into classical formulations that do not list it, and it should not be added to popular cough powders merely because they are used for kasa or svasa.

For digestive use, the safer classical framing is deepana and ruchya, meaning support for appetite and digestive stimulation in a suitable constitution and clinical context. It should not be promoted as a general replacement for medical evaluation of reflux, gastritis, ulcers, iron deficiency, malabsorption, or chronic abdominal complaints.

For urinary acidification, ammonium chloride has a recognized modern pharmacological role, but this is a physician-supervised acid-base intervention rather than a home Ayurvedic UTI protocol. Urinary pH manipulation can be harmful when used without diagnosis, urinalysis, renal assessment, and monitoring.

Absolute and Practical Contraindications

Nausadar-containing internal preparations should be avoided in severe renal impairment, severe hepatic impairment, known metabolic acidosis, suspected ammonia-handling disorders, and unsupervised pregnancy or lactation. Prescription labeling for ammonium chloride states that it is contraindicated in severe renal or hepatic impairment and that pregnancy use requires clear medical need. These cautions are directly relevant when considering any internal preparation containing ammonium chloride.

Extra caution is also warranted in children, older adults, people with chronic lung disease, people with heart disease or edema, and anyone taking medicines where urinary pH, electrolyte status, kidney function, or acid-base balance is clinically important. A product containing Nausadar should be stopped and medical care sought if there is unusual weakness, confusion, deep or irregular breathing, persistent vomiting, severe abdominal discomfort, faintness, or worsening respiratory symptoms.

Quality-Control Red Flags

The safest Nausadar-containing preparation is one that is made by a qualified manufacturer or pharmacy, uses correctly identified and purified material, states the full composition, and is prescribed by a qualified Ayurvedic physician. Products should be avoided when the label hides mineral ingredients, uses vague “proprietary” wording for a Rasaushadhi, lacks manufacturer details, lacks batch testing, or encourages long-term unsupervised use.

Concerns about heavy metals in some untested Ayurvedic and traditional products make sourcing especially important. This does not mean every Rasa Shastra medicine is unsafe, but it does mean mineral preparations require stricter quality assurance than ordinary food herbs. Raw industrial ammonium chloride, soldering flux material, laboratory reagent, fertilizer-grade material, or bazaar Nausadar should never be used as medicine.

Responsible Bottom Line

Nausadar is best understood as a potent mineral-pharmaceutical ingredient with a narrow responsible-use window. Classical Ayurveda places it within processed mineral pharmacy, and modern pharmacology explains why it may act as an expectorant and acidifying agent while also explaining its risks. The balanced conclusion is neither blanket rejection nor casual promotion: use only purified or pharmaceutically standardized material, only in appropriate compound preparations, only at practitioner-directed doses, and only after contraindications have been excluded.

Medical Disclaimer: This safety review is for educational purposes only. Nausadar-containing preparations should be used only under the supervision of a qualified Ayurvedic physician or licensed healthcare provider who can assess contraindications, product quality, dose, and monitoring needs. Do not self-prescribe mineral preparations, and do not use raw Nausadar as medicine.

References

1. Pubchem (pubchem.ncbi.nlm.nih.gov)
2. Ncismindia (ncismindia.org)
3. Medicaljournals (medicaljournals.stmjournals.in)
4. Archive (archive.org)
5. Labeling (labeling.pfizer.com)
6. Labeling (labeling.pfizer.com)
7. Go (go.drugbank.com)
8. Hpvchemicals (hpvchemicals.oecd.org)
9. Hpvchemicals (hpvchemicals.oecd.org)
10. Merckvetmanual (merckvetmanual.com)
11. FDA
12. Stacks (stacks.cdc.gov)

The male hypogonadism consultation has become more complex because many men now arrive with symptoms, laboratory values in the borderline or low range, and awareness of both pharmaceutical testosterone replacement therapy and Ayurvedic vajikarana care. A useful comparison must begin with a clear distinction: testosterone replacement therapy and vajikarana are not identical substitutes. TRT is exogenous hormone replacement for medically diagnosed testosterone deficiency, while vajikarana is an Ayurvedic branch concerned with virility, fertility, sexual function, reproductive vitality, and the nourishment of shukra dhatu.

The comparison is clinically valuable because it clarifies where conventional hormone replacement is clearly indicated, where fertility-preserving support may be preferable, and where an integrative plan can address reversible contributors such as obesity, sleep disruption, metabolic disease, stress, medication effects, or chronic illness. The meaningful testosterone therapy Ayurveda vajikarana comparison is therefore not a contest between two equivalent therapies, but a decision framework based on diagnosis, fertility goals, severity of deficiency, safety monitoring, and the patient’s broader health picture.

TRT: Evidence, Outcomes, and Risk Profile

In conventional medicine, testosterone therapy is intended for men with clinical hypogonadism, not for general vitality enhancement. Diagnosis requires symptoms or signs compatible with testosterone deficiency and consistently low testosterone on properly timed testing, commonly confirmed with at least two early-morning measurements. The American Urological Association uses a total testosterone level below 300 ng/dL as a reasonable diagnostic cut-off, while the Endocrine Society emphasizes symptoms, repeat morning testing, accurate assays, reference ranges, and evaluation of the cause of deficiency. Luteinizing hormone and follicle-stimulating hormone help distinguish primary testicular failure from secondary hypothalamic-pituitary causes.

For properly selected men with confirmed hypogonadism, TRT can improve several clinically important outcomes. The most consistent benefits are in sexual desire, erectile function, and sexual activity. Testosterone therapy can also improve anemia in some men, increase bone mineral density, and increase lean body mass, while effects on energy, mood, physical performance, and cognition are less predictable. This distinction matters because a man with true primary hypogonadism is different from a man with borderline testosterone related to weight gain, poor sleep, or metabolic syndrome.

The risk profile of TRT requires medical supervision. Exogenous testosterone can raise hematocrit and cause erythrocytosis, so hematocrit monitoring is standard. It can suppress spermatogenesis through hypothalamic-pituitary-gonadal axis suppression, making it unsuitable for men who want to preserve fertility in the near term. TRT is also avoided or used with particular caution in men with conditions such as prostate or breast cancer, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, recent myocardial infarction or stroke, thrombophilia, or other contraindications identified by the treating physician.

Cardiovascular safety has been clarified for appropriately selected men but not for misuse or supraphysiological dosing. In the TRAVERSE trial, 5,246 men aged 45 to 80 years with symptoms of hypogonadism, testosterone below 300 ng/dL, and pre-existing or high cardiovascular risk were assigned testosterone gel or placebo. Testosterone therapy was non-inferior to placebo for major adverse cardiac events in that population, while pulmonary embolism, atrial fibrillation, nonfatal arrhythmia, and acute kidney injury were reported more often in the testosterone group. This supports careful prescribing and monitoring rather than casual use.

TRT is most straightforward when the body cannot produce adequate testosterone, especially in primary testicular failure. In secondary hypogonadism, the clinical task is broader: assess reversible contributors, medication effects, sleep disorders, obesity, diabetes, chronic illness, pituitary disease, and fertility goals before deciding whether exogenous testosterone is the right intervention. This is the area where vajikarana and lifestyle-centered care become most relevant as conservative or adjunctive support.

Vajikarana: The Ayurvedic Framework and Clinical Data

Vajikarana is described in classical Ayurveda as a branch of care concerned with virility, fertility, semen quality, sexual capacity, progeny, and the strengthening of reproductive vitality. The term is traditionally connected with vaji, the horse, as a symbol of strength and sexual vigor. It is not a classical synonym for testosterone replacement therapy. Its framework is broader: diet, conduct, rejuvenative measures, sleep, mental state, digestion, tissue nourishment, and selected vrishya and rasayana substances are used to support shukra dhatu and reproductive health.

Three commonly discussed substances in contemporary vajikarana-style testosterone and fertility support are ashwagandha, purified shilajit, and kapikacchu. In the Ayurvedic Pharmacopoeia of India, ashwagandha root is described with tikta and kashaya rasa, laghu guna, ushna virya, madhura vipaka, and actions including rasayana, balya, and vajikarana. Atmagupta or kapikacchu is identified with Mucuna pruriens and described with tikta and kashaya rasa, guru and snigdha guna, shita virya, katu vipaka, and actions including vrishya, brimhana, balya, and vajikarana. Shilajit is a purified mineral pitch used in Ayurvedic practice, and product purity is especially important because crude or contaminated preparations are not appropriate for self-use.

Ashwagandha (Withania somnifera) has human clinical data relevant to strength, fertility, and androgen markers. In a randomized placebo-controlled trial in healthy young men undergoing resistance training, 600 mg daily of ashwagandha root extract for eight weeks was associated with greater increases in testosterone than placebo, along with gains in muscle strength and recovery. In a pilot randomized placebo-controlled trial in oligospermic men, 675 mg daily of ashwagandha root for 90 days was associated with improved sperm concentration, semen volume, motility, testosterone, and luteinizing hormone. In overweight men aged 40 to 70 years with mild-to-moderate fatigue, an eight-week ashwagandha extract trial reported increases in salivary testosterone and DHEA-S compared with placebo.

Shilajit, when purified and standardized, has also been evaluated in men. In a randomized double-blind placebo-controlled trial of healthy men aged 45 to 55 years, purified shilajit 250 mg twice daily for 90 days increased total testosterone, free testosterone, and DHEA-S compared with placebo. This does not make shilajit a replacement for TRT in primary hypogonadism, but it supports its role as a carefully selected adjunct within a broader reproductive vitality protocol when medically appropriate.

Kapikacchu or Mucuna pruriens is a classical vajikarana drug and a contemporary fertility-support herb. Modern fertility studies commonly use the seed, which is known for L-DOPA content. In a clinical study of infertile men, Mucuna pruriens treatment was associated with improved testosterone, luteinizing hormone, dopamine and catecholamine markers, sperm count, and sperm motility. This makes kapikacchu especially relevant where low reproductive vitality overlaps with impaired semen parameters, though it must be used cautiously in people taking dopaminergic medicines, psychiatric medicines, or treatment for neurological disease.

The Clinical Decision Framework

The appropriate choice depends on the diagnosis, not on ideology. TRT is generally the stronger and more direct option when a man has confirmed pathological hypogonadism, especially primary testicular failure, persistent symptoms, consistently low morning testosterone, and no near-term fertility goal. It requires physician supervision, laboratory monitoring, attention to contraindications, and realistic expectations about benefits and risks.

Vajikarana is more appropriate as a first-line supportive framework when testosterone is borderline or mildly low in the setting of reversible contributors, when fertility preservation is important, when semen parameters are suboptimal, or when the clinical goal is reproductive vitality rather than hormone replacement. It is also a reasonable adjunctive framework for diet, sleep, exercise, stress regulation, and carefully selected herbs under professional guidance. It should not be presented as a stand-alone cure for primary hypogonadism or used to delay necessary medical evaluation.

An integrative approach often makes the most clinical sense for secondary or borderline presentations. Conventional evaluation can identify endocrine disease, pituitary disease, medication effects, diabetes, obesity, sleep apnea, anemia, and cardiovascular risk. Ayurvedic assessment can add attention to digestion, tissue nourishment, sleep rhythm, strength, sexual vitality, mental state, and shukra dhatu. The low testosterone Ayurveda protocol can be used as an educational companion to practitioner-led care, not as a substitute for diagnosis.

Medical Disclaimer: This comparison is for educational purposes only. Testosterone management requires proper laboratory testing and evaluation by a qualified endocrinologist, urologist, or healthcare provider. Do not self-prescribe TRT, high-dose herbs, shilajit, kapikacchu, or testosterone-boosting supplements without professional guidance. Consult a qualified Ayurvedic practitioner before beginning vajikarana herbs or protocols, especially if you have a medical condition, are trying to conceive, take prescription medicines, have liver, kidney, prostate, cardiovascular, psychiatric, endocrine, or sleep-related concerns, or are using fertility treatment.

References

1. Endocrine (endocrine.org)
2. Auanet (auanet.org)
3. Academic (academic.oup.com)
4. Endocrine (endocrine.org)
5. Acc (acc.org)
6. Charaka Samhita — Vajikarana Adhyaya
7. Ayurvedic Pharmacopoeia of India
8. Ayurvedic Pharmacopoeia of India
9. Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial (2015), PubMed
10. Clinical Evaluation of the Spermatogenic Activity of the Root Extract of Ashwagandha (Withania somnifera) in Oligospermic Males: A Pilot Study (2013), PubMed Central
11. A Randomized, Double-Blind, Placebo-Controlled, Crossover Study Examining the Hormonal and Vitality Effects of Ashwagandha ( Withania somnifera) in Aging, Overweight Males (2019), PubMed Central
12. Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers (2016), PubMed
13. Review on shilajit used in traditional Indian medicine (2011), PubMed
14. Journals (journals.plos.org)
15. Mucuna pruriens improves male fertility by its action on the hypothalamus-pituitary-gonadal axis (2009), PubMed
16. Examining the Effects of Herbs on Testosterone Concentrations in Men: A Systematic Review (2021), PubMed Central
17. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials (2013), PubMed